What is it about?
Identification of shared oncoproteins among various subtypes of NSCLC is critical for future targeted therapies. This study uncovers the AAA+ ATPase Reptin to be highly expressed in the vast majority of pulmonary adenocarcinoma and squamous cell carcinoma patient samples and associated with dismal outcome. Reptin colocalized with HDAC1 in NSCLC cells, and both, direct targeting of Reptin as well as specific inhibition of its interaction partner resulted in severe impairment of tumor cell proliferation. Moreover, pharmacological disruption of the Reptin/HDAC1 complex mediated significant sensitization of NSCLC cells to chemotherapy. The axix Reptin/HDAC1 is an attractive novel target for NSCLC therapy.
Featured Image
Why is it important?
• Reptin is highly expressed in the vast majority of NSCLC patients • Overexpression of Reptin is associated with poor prognosis of NSCLC patients • Knock down of Reptin in NSCLC cells impairs tumor cell growth in vitro and in vivo • Disruption of Reptin/HDAC1 complex sensitizes NSCLC cells to chemotherapy
Perspectives
As a cancer research scientist it has been a pleasure to uncover the Reptin-HDAC-partner axis in lung cancer. Our results on this project has been so strongly reproducible and clear that have motivated us to keep on looking deep into this complex not only in our laboratory but also in a clinical study that hopefully will benefit future lung cancer patients and it will increase our knowledge in this complex area of cancer.
Maria Francisca Arteaga
Westfalische Wilhelms-Universitat Munster
Read the Original
This page is a summary of: Reptin drives tumour progression and resistance to chemotherapy in nonsmall cell lung cancer, European Respiratory Journal, May 2018, European Respiratory Society (ERS),
DOI: 10.1183/13993003.01637-2017.
You can read the full text:
Contributors
The following have contributed to this page
